Drug pricing has emerged as a major concern across the country and is even beginning to factor into the US presidential race. Outlandish prices for lifesaving generic drugs such as Daraprim and the EpiPen have caused people to doubt the value of all medicines, both new and old. This view was further fueled recently by a study reported in the Journal of the American Medical Association in which the authors created a simulation model (“The Cardiovascular Disease Policy Model”) to evaluate the cost-effectiveness of PCSK9 inhibitors in those eligible for treatment based on the approved FDA labels for these medications.
